PMID- 17386384
OWN - NLM
STAT- MEDLINE
DCOM- 20070419
LR  - 20181113
IS  - 1532-6551 (Electronic)
IS  - 1071-3581 (Linking)
VI  - 14
IP  - 2
DP  - 2007 Apr
TI  - A novel clinical indicator using Tc-99m sestamibi for evaluating cardiac 
      mitochondrial function in patients with cardiomyopathies.
PG  - 215-20
AB  - BACKGROUND: Technetium 99m sestamibi (MIBI) is a technetium-labeled myocardial 
      perfusion agent that is taken up by the myocardial cell in proportion to 
      myocardial regional blood flow and remains fixed in the myocardial cell over a 
      long period of time. Previous studies have suggested that MIBI shows very slow 
      myocardial clearance after its initial uptake in an animal model, which is 
      related to mitochondrial function. This study was designed to test the hypothesis 
      that MIBI washout can be used to evaluate the severity of congestive heart 
      failure in comparison to other clinical parameters in patients with 
      cardiomyopathies. METHODS AND RESULTS: After administration of MIBI, 61 patients 
      with nonischemic congestive heart failure (49 with dilated cardiomyopathy and 12 
      with other cardiomyopathies) and 7 normal control subjects were examined by 
      electrocardiography-gated myocardial perfusion single photon emission computed 
      tomography and planar data acquisition in the early and delayed phases (interval 
      of 3 hours). Myocardial MIBI washout rates were calculated from the early and 
      delayed planar images. Left ventricular function (systolic and diastolic) was 
      analyzed by use of QGS data. Plasma levels of B-type natriuretic peptide and 
      iodine 123 metaiodobenzylguanidine (MIBG) parameters were also measured. Patients 
      were followed up for a mean of 12 months (range, 1-19 months). As the severity of 
      the New York Heart Association (NYHA) functional class advanced, the washout rate 
      of MIBI increased (21.6% +/- 2.4% in those with NYHA class I [n = 23], 28% +/- 4% 
      in those with NYHA class II [n = 27], and 35% +/- 5% in those with NYHA class III 
      [n = 10]; P < .05, analysis of variance). The washout rate of MIBI was positively 
      correlated with the level of B-type natriuretic peptide (r = 0.31, P < .05), 
      end-diastolic volume (r = 0.396, P < .01), and end-systolic volume (r = 0.496, P 
      < .01) and was negatively correlated with left ventricular ejection fraction (r = 
      0.523, P < .01), peak filling rate (r = 0.444, P < .01), and first-third ejection 
      fraction (r = 0.414, P < .01). The parameters of MIBG scintigraphy were 
      calculated as the heart-mediastinum count ratio (1.9 +/- 3) and washout rate (38% 
      +/- 4%). We found a significant relationship between the washout rate of MIBI and 
      the heart-mediastinum count ratio of MIBG (r = 0.51, P < .01). Patients with a 
      higher washout rate of MIBI had a higher cardiac event rate (> or =28%) than 
      those with a lower washout rate (<28%) (P < .05). CONCLUSIONS: The myocardial 
      washout rate of MIBI is thought to be a novel marker for the diagnosis of 
      myocardial damage or dysfunction, providing prognostic information in patients 
      with congestive heart failure.
FAU - Matsuo, Shinro
AU  - Matsuo S
AD  - Department of Cardiovascular and Respiratory Medicine, Shiga University of 
      Medical Science, Shiga, Japan. smatsuo@belle.shiga-med.ac.jp
FAU - Nakae, Ichiro
AU  - Nakae I
FAU - Tsutamoto, Takayoshi
AU  - Tsutamoto T
FAU - Okamoto, Noriake
AU  - Okamoto N
FAU - Horie, Minoru
AU  - Horie M
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Nucl Cardiol
JT  - Journal of nuclear cardiology : official publication of the American Society of 
      Nuclear Cardiology
JID - 9423534
RN  - 0 (Radiopharmaceuticals)
RN  - 971Z4W1S09 (Technetium Tc 99m Sestamibi)
SB  - IM
MH  - Aged
MH  - Cardiomyopathies/*diagnostic imaging/*metabolism
MH  - Computer Simulation
MH  - Female
MH  - Gated Blood-Pool Imaging/methods
MH  - Humans
MH  - Image Interpretation, Computer-Assisted/*methods
MH  - Male
MH  - Metabolic Clearance Rate
MH  - Middle Aged
MH  - Mitochondria, Heart/*diagnostic imaging/*metabolism
MH  - Models, Cardiovascular
MH  - Radiopharmaceuticals/pharmacokinetics
MH  - Technetium Tc 99m Sestamibi/*pharmacokinetics
EDAT- 2007/03/28 09:00
MHDA- 2007/04/20 09:00
CRDT- 2007/03/28 09:00
PHST- 2006/09/27 00:00 [received]
PHST- 2006/10/31 00:00 [revised]
PHST- 2006/10/31 00:00 [accepted]
PHST- 2007/03/28 09:00 [pubmed]
PHST- 2007/04/20 09:00 [medline]
PHST- 2007/03/28 09:00 [entrez]
AID - S1071-3581(07)00031-1 [pii]
AID - 10.1016/j.nuclcard.2006.10.022 [doi]
PST - ppublish
SO  - J Nucl Cardiol. 2007 Apr;14(2):215-20. doi: 10.1016/j.nuclcard.2006.10.022.